Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3.1 CAD | -3.43% | +4.38% | +45.54% |
Summary
- Overall, and from a short-term perspective, the company presents an interesting fundamental situation.
Strengths
- Growth is a substantial asset for the company, as anticipated by dedicated analysts. Within the next three years, growth is estimated to reach 54% by 2026.
- The company shows low valuation levels, with an enterprise value at 0.53 times its sales.
- For the last 4 months, the company has been enjoying highly positive EPS revisions, which were frequently and significantly raised.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
- Over the past twelve months, analysts' opinions have been strongly revised upwards.
Weaknesses
- As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
- Low profitability weakens the company.
- The valuation of the company is particularly high given the cash flows generated by its activity.
- Revenue estimates are regularly revised downwards for the current and coming years.
- For the past year, analysts have significantly revised downwards their profit estimates.
- Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
- The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
- The group usually releases earnings worse than estimated.
Ratings chart - Surperformance
Sector: Drug Retailers
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+45.54% | 186M | - | ||
+17.55% | 3.01B | D+ | ||
+15.99% | 1.73B | - | ||
+3.18% | 492M | - | ||
-4.48% | 104M | - | ||
+0.97% | 98.08M | - | - | |
+56.25% | 73.36M | - | C | |
+44.94% | 53.21M | - | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
- Stock Market
- Equities
- HITI Stock
- Ratings High Tide Inc.